

Ref. No.: WOCK/SEC/SE/2024-25/048

23rd September, 2024

BSE Limited Corporate Relations Department P J Towers Dalal Street Mumbai - 400 001 <u>Scrip Code: 532300</u>	National Stock Exchange of India Limited Exchange Plaza Bandra Kurla Complex Bandra (E) Mumbai - 400 051 <u>NSE Symbol: WOCKPHARMA</u>
--------------------------------------------------------------------------------------------------------------------------------------------	---------------------------------------------------------------------------------------------------------------------------------------------------------------------

Dear Sir/ Madam,

Subject: Submission pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") - Press Release

Pursuant to Regulation 30 of Listing Regulations, please find enclosed Press Release -"Dr. Habil Khorakiwala bestowed Lifetime Achievement Award by Integrated Health and Wellbeing Council in Dubai".

A copy of the same will also be uploaded on the Company's website www.wockhardt.com

Kindly take the same on record please.

Thanking you,

For Wockhardt Limited

Rashmi Mamtura
Company Secretary

Encls: A/a

Dr. Habil Khorakiwala bestowed Lifetime Achievement Award by Integrated Health and Wellbeing Council in Dubai



Founder Chairman of Wockhardt group, Dr. Habil Khorakiwala was presented the Lifetime Achievement Award at the 10th Integrated Health & Wellbeing (IHW) Summit, a premier think-tank council engaged in public health advocacy and focused on promoting health, wellness and holistic well-being.

The esteemed advisory board recognized the exceptional contributions and lifelong dedication of Dr. Habil Khorakiwala to transform the healthcare landscape in India and globally.

The IHW Council in its statement lauded his visionary leadership as the Founder Chairman of Wockhardt which has been pivotal in advancing healthcare accessibility and quality. The Council acknowledged his unparalleled contributions towards unwavering commitment to innovation, patient care and integration of global standards setting a new benchmark in the industry. His pioneering efforts has maintained a balance between affordability and excellence in healthcare, thus leaving a lasting impact on countless lives. His extraordinary leadership serves as an inspiration fostering continued progress towards the shared vision of holistic health and wellbeing for all.

Under the visionary leadership of Dr. Habil Khorakiwala over the period of 25 years, Wockhardt has focused its research efforts in the area of discovering novel medicines for multi-drug resistant infections. This has resulted in a portfolio of 6 novel antibiotics at various stages of clinical development and commercialization, each have been granted Qualified Infectious Disease Product status by the US FDA. Wockhardt's flagship novel mechanism-based antibiotic, ZaynichTM (Zidebactam/Cefepime), designed to target extreme-drug resistant Gram negative infections, is undergoing a global Phase 3 study. Zaynich has already saved lives of more than 35 critically ill patients under compassionate use over last

one year and is also being evaluated in a clinical study involving patients with documented meropenem-resistant infections.

Dr. Habil Khorakiwala is also ex-President of FICCI & has played an important role in India's bilateral relations & nation building effort.

On his behalf, the award was accepted by Dr. Huzaifa Khorakiwala (Executive Director of Wockhardt and CEO of Wockhardt Foundation) at the 10th edition of Integrated Health and Wellbeing Summit & Global Health Leaders Awards held on 21st September, 2024, at the Hyatt Regency in Deira Dubai.

About Wockhardt:

Wockhardt is a research based Global Pharmaceutical and Biotech company. Wockhardt's New Drug Discovery programme has focussed on unmet need of Anti-bacterial drugs that are effective against the menace of untreatable superbugs. Wockhardt is the only company in the world where USFDA has given QIDP Status (Qualified Infectious Disease Product) for 6 of its Anti-bacterial discovery programmes – 3 of them are Gram Negative and 3 Gram Positive effective against untreatable "Superbugs". Employing around ~2600 people and 27 nationalities, it has a presence in USA, UK, Ireland, Switzerland, France, Mexico, Russia and many other countries. It has manufacturing and research facilities in India & UK and a manufacturing facility in Ireland. Around 78% of its global revenues coming from international businesses.

***Wockhardt Hospitals** is one of the leading multispecialty hospital chain spread across India, providing world-class healthcare services. It operates 5 hospitals across western India cities: Mumbai & Nagpur (2 hospitals each), and 1 in Rajkot. It has treated around 3 million patients so far and offers services across 30+ speciality and super-specialties through its 1,400+ doctors.*

***Wockhardt Foundation** is a national, not-for-profit organization engaged in social service and human welfare activities. Its programmes have made a perceptible change in its areas of operation to the lives of the underprivileged. The work of Wockhardt Foundation has been well recognized in the outside world with it being the recipient of many Awards including the prestigious 'Asia Healthcare Excellence Award for the Best CSR Practice in Healthcare.*

About Integrated Health & Wellbeing Council:

Integrated Health & Wellbeing (IHW) Council is a premier think tank, engaging in everything concerned with health and wellbeing of human enterprise and existence. A not-for-profit organization, IHW Council is registered under Section 8 of Companies Act 2013, with its head office in Delhi, India. Nine years journey of the Integrated Health & Wellbeing Council inspired by UN global agenda of holistic approach to Sustainable Development Goals (SDG) is a great continuous learning experience to help improving good health and lifestyle of people at large. It drives 9 out of 17 SDG goals through holistic Hi5 health awareness, advocacy and action agenda of the IHW Council.